Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Saptalis Launches LIKMEZ®—Only FDA-Approved Ready-to-Use Metronidazole Suspension
Details : Likmez (metronidazole) is an antimicrobial, which works by inhibiting of DNA synthesis, it is indicated for trichomoniasis in adults.
Product Name : Likmez
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Appili Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
Details : Likmez(metronidazole) is a taste-masked liquid oral reformulation of metronidazole which effectively treats Clostridium difficile infection (CDI) in children by inhibiting protein synthesis by interacting with DNA leading cell death in susceptible organi...
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 25, 2023
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Appili Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Details : Under the terms of the amended agreement, Saptalis will assume responsibility for development and commercialization of ATI-1501 in Europe and Latin America (collectively, the “Expanded Territories”).
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
August 02, 2022
Lead Product(s) : Metronidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Appili Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Biorasi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2019
Lead Product(s) : Permethrin
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Biorasi
Deal Size : Inapplicable
Deal Type : Inapplicable